Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in ...

Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, OCREVUS, in reduc ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new late-breaking data from the Phase III FENtrepid study showing the investigational Bruton's tyrosine kinase (BTK ...

Experts say dangerous sleep apnoea affects an estimated 8 million in the UK alone, and everything from evolution to obesity or even the climate crisis could be to blame ...

Detailed price information for Tg Therapeutics (TGTX-Q) from The Globe and Mail including charting and trades.

Hollywood has a way of keeping beauty intact, even more so than for the rest of us ordinary folks. The collection of stunning ...